Glox Therapeutics

Executive Summary

Glox Therapeutics is a UK-based biotechnology company founded in 2019, focused on developing precision antibiotics to combat antimicrobial resistance (AMR). Leveraging over 20 years of research, the company engineers protein bacteriocins that specifically target drug-resistant Gram-negative pathogens, including Pseudomonas aeruginosa and Klebsiella pneumoniae. These pathogens are critical threats in hospital-acquired infections, and current antibiotics are increasingly ineffective. Glox's approach offers a novel mechanism of action, potentially reducing the risk of resistance development. The company is private and has not disclosed total funding or valuation, indicating an early stage of development. Given the global urgency of AMR, Glox's platform could address a significant unmet medical need, though the path to market requires successful preclinical and clinical validation.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Proof-of-Concept Data for Lead Candidate45% success
• Q4 2026Series A Funding Round50% success
• Q1 2027Licensing or Collaboration Agreement with Pharma Partner30% success